Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P4 (ribosomal protein L21 pseudogene 4) is a processed pseudogene located in the human genome. Pseudogenes like RPL21P4 are sequences that originated via retrotransposition or duplication of a functional ancestor (here, the ribosomal protein L21 gene), but have since lost their protein-coding capacity due to disabling mutations or lack of regulatory sequences. RPL21P4 does not encode a functional protein and is considered non-coding; it has no known function, biological activity, or value as a drug target. Pseudogenes of ribosomal proteins are common and distributed throughout the human genome; the RPL21 gene itself has numerous associated pseudogenes, but only the functional RPL21 encodes a component of the ribosomal 60S subunit involved in protein synthesis. There are currently no known disease, biomarker, or drug associations with RPL21P4. If your focus is on potential therapeutic targets or functional gene products, you likely want to consult the functional gene "Ribosomal protein L21" (abbreviation RPL21), not RPL21P4.
None.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 4 (RPL21P4).